DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Addendum su RenovoRx (RNXT) dopo JPM 2026 – M&A, patent cliff e precision oncology
RNXT – JPM 2026, M&A Wave & Precision Oncology Context (Addendum)
Language
1. Executive summary – Where RNXT sits after JPM 2026
RenovoRx (RNXT) just presented at the J.P. Morgan Healthcare Conference in a macro-environment that is very different from the one we had even 12–18 months ago:
- Biopharma M&A has re-accelerated, with 2025 already back to >$130B of deal value and 2026 expected to be another active year as large pharma tries to refill pipelines.
- Large caps face a massive patent cliff into 2030–2032 (hundreds of billions of dollars of revenue at risk), and oncology – especially precision oncology – is one of the preferred hunting grounds.
- The precision oncology market itself is forecast to roughly double by 2032, with high single-digit CAGRs driven by targeted therapies, biomarkers, AI and interventional approaches.
RNXT is obviously not on the same size planet as mega-deal targets like Revolution Medicines, but it sits exactly at the intersection of two themes the JPM crowd cares about:
- Precision/interventional oncology in a hard indication (locally advanced pancreatic cancer) with a Phase 3 in progress.
- A drug-device combo platform (TAMP + RenovoCath) that could be bolt-on for either an oncology pharma or an interventional medtech player.
This addendum does not change the core RNXT thesis (still binary around TIGeR-PaC OS in 2027), but frames how the current M&A wave, patent cliff and precision oncology boom could affect the strategic optionality around the name.
2. Macro backdrop – M&A wave and patent cliff
2.1 Biopharma dealmaking heading into 2026
According to recent Q4 2025 deal reports and sector overviews, biopharma M&A has already rebounded strongly:
- 2025 closed with 100+ biopharma deals and total value in the $130–140B range, materially above 2024.
- The J.P. Morgan team and several industry trackers highlight that deal activity is expected to remain high in 2026, with both “string-of-pearls” bolt-ons and selected megamergers.
- Oncology, neuroscience and cardiometabolic disease (obesity in particular) are core focus areas.
Headlines around JPM 2026 are dominated by larger names (e.g. Merck circling Revolution Medicines, Lilly and others doing $10B+ oncology deals), but the logic that drives these moves also cascades down to the small-cap layer where RNXT lives.
2.2 The patent cliff that forces Big Pharma to buy
Multiple analyses (JPM, banks, media) converge on the same picture:
- By ~2030, $150B+ of annual revenue is expected to go off patent for large-cap pharma/biotech, often representing ~30–35% of current sales for individual companies.
- Looking out to 2032, estimates of total revenue at risk (including smaller brands) span roughly $200–350B.
- Oncology blockbusters (PD-1/PD-L1, targeted TKIs) are central to that cliff, forcing incumbents to look for new oncology assets years before expiry.
The practical consequence is that small-cap oncology names are once again “in play” structurally: not all of them will be bought (far from it), but the bid for innovation is back. That is the environment in which RNXT is now trying to tell its story at JPM and ASCO GI.
3. Precision oncology and interventional platforms
3.1 A market that is quietly doubling
Recent market research reports estimate that the global precision oncology market was around $100–110B in 2023–2024 and is expected to grow to roughly $200–230B by 2032, a CAGR of about 9–10%.
Key drivers cited:
- expanding use of genomic profiling and biomarkers;
- growth in targeted therapies and tumor-agnostic indications;
- integration of AI and big data in diagnostics and treatment;
- rising use of companion diagnostics and liquid biopsies.
Most of the data and commentary focus on molecular precision oncology (NGS, CDx, targeted drugs). RNXT is in a slightly different niche: procedural / interventional precision oncology – physically altering where and how the drug is delivered rather than altering the drug itself.
3.2 Where RNXT’s TAMP fits in that landscape
RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) platform and the RenovoCath catheter are effectively an attempt to make chemotherapy more “precise” by:
- concentrating the drug in the tumour region (arterial segment feeding the lesion),
- reducing systemic exposure and, potentially, systemic toxicity,
- enabling interventional oncologists/radiologists to control delivery in a highly localised way.
In a world where precision oncology is a major capital magnet and M&A theme, RNXT is one of the few micro-caps offering a Phase 3-ready, device-enabled delivery platform in pancreatic cancer – an indication that is both clinically devastating and commercially interesting for big pharma (given the unmet need).
4. Regulatory backdrop – accelerated approval, surrogates and OS
Several recent articles and analyses have looked at the impact of the FDA’s accelerated approval (AA) pathway in oncology:
- Some studies highlight that AA drugs have delivered meaningful gains in progression-free and overall survival in a subset of indications and patients, especially where they opened earlier access to transformative agents.
- Other work shows a more mixed picture: only a portion of AA oncology drugs ultimately demonstrate a clear survival benefit within 5 years, and regulators have been increasingly willing to request confirmatory data or even withdraw labels when benefit fails to materialise.
For RNXT, TIGeR-PaC is not an “AA-style” programme: it is powered on overall survival (OS) with a classic confirmatory endpoint. However, the regulatory culture around endpoints and surrogate markers matters:
- The PK/PD sub-study at ASCO GI (showing lower systemic exposure and biomarker correlations) feeds into the broader discussion on how to evaluate benefit/risk for novel delivery platforms.
- If regulators accept strong mechanistic data plus OS in LAPC, TAMP may later be positioned for additional indications where surrogate endpoints (e.g. biomarkers, imaging) play a larger role.
The key point is that regulators are cautious but not closed to innovative oncology approaches. They ask for real benefit (and have become stricter on low-value AAs), but when a platform demonstrates a convincing risk/benefit profile, the environment still rewards it.
5. What all this means for RNXT – after JPM
5.1 RNXT is in a “thematically right” spot, but still micro-cap risky
If we overlay the macro themes on RNXT:
- Theme fit: pancreatic cancer, precision/interventional oncology, drug-device combo, Phase 3 asset – all lines up with what big pharma and medtech say they want to buy.
- Valuation: a market cap around a few dozen million dollars makes RNXT tiny relative to the TAM, but also means high volatility and financing risk.
- Data path: the real value inflection is still the final OS readout in 2027; ASCO GI 2026 and PanTheR/real-world data are supporting blocks.
The JPM 2026 presentation essentially puts RNXT on the “radar wall” in San Francisco: not as a front-row M&A candidate, but as a name that fits several checkboxes if TIGeR-PaC succeeds.
5.2 Potential acquirers – pharma vs medtech vs hybrid
Without speculating on individual companies, three broad buckets of potential partners/acquirers exist:
- Oncology-focused pharma looking to expand in pancreatic cancer and interventional oncology.
- Interventional / medtech players (catheters, embolisation, IO devices) wanting to add a drug-based oncology platform on top of their installed base.
- Hybrid strategics (pharma with IO divisions) that can absorb both the drug and the device side.
In practice, any strategic interest will almost certainly depend on:
- final TIGeR-PaC OS data and safety profile,
- PanTheR real-world uptake and RenovoCath revenue trajectory,
- RNXT’s ability to maintain Nasdaq listing and manageable dilution.
5.3 Key questions to ask now
After JPM, a few questions become even more relevant:
- Is management clearly open to business development (partnering / regional deals) or focused on going fully alone?
- How far does the current cash take them post-ASCO GI and through full TIGeR-PaC enrollment, and what form might the next financing take?
- How much of the post-JPM “interest” is tangible (meeting requests from strategics) vs. just ambient sector noise?
None of this is a prediction that RNXT will be acquired. The point is that, post-JPM 2026, the external environment is more favourable for oncology bolt-ons than it has been in years: if RNXT delivers on its own clinical and execution milestones, it will be doing so with a macro wind at its back rather than in its face.
6. Disclaimer (EN)
This addendum is for educational and informational purposes only. It is not investment advice, not a solicitation to buy or sell securities, and not a personalised recommendation. The information is based on public filings, company communications and reputable news/market reports available at the time of writing and may change or contain errors.
Readers should always verify data directly from primary sources (SEC filings, FDA documents, official press releases, conference materials) and make their own independent decisions, possibly with the help of a licensed financial advisor. Trading small-cap biotech and catalyst-driven stocks is risky and may lead to a total loss of capital.
For full legal and privacy information, please refer to:
Disclaimer
and
Termini di Servizio, Privacy, Cookie Policy // Term of Service, Privacy, Cookie Policy
.
1. Executive summary – Dove si colloca RNXT dopo JPM 2026
RenovoRx (RNXT) ha presentato a JPM 2026 dentro un contesto macro molto diverso rispetto a quello di 12–18 mesi fa:
- le M&A biopharma sono tornate forti, con il 2025 già oltre i 130 miliardi di dollari di deal e aspettative di elevata attività anche per il 2026;
- le big pharma si trovano davanti a un “patent cliff” enorme entro il 2030–2032 (centinaia di miliardi di ricavi a rischio) e l’oncologia – in particolare la precision oncology – è uno dei terreni preferiti su cui comprare;
- il mercato della precision oncology è previsto raddoppiare circa entro il 2032, con CAGR a una cifra alta trainati da terapie mirate, biomarcatori, AI e approcci interventional.
RNXT non è certo nella stessa categoria di valore di target come Revolution Medicines, ma si trova esattamente all’incrocio di due temi che a JPM sono sotto i riflettori:
- oncologia di precisione / interventional in una indicazione dura (LAPC) con uno studio di Fase 3 in corso;
- una piattaforma farmaco-dispositivo (TAMP + RenovoCath) potenzialmente integrabile sia da un player pharma oncologico sia da un medtech/interventional.
Questo addendum non cambia la tesi principale su RNXT (resta binaria intorno ai dati OS di TIGeR-PaC nel 2027), ma inquadra come ondata M&A, patent cliff e boom della precision oncology influenzano l’opzionalità strategica sul titolo.
2. Contesto macro – M&A e patent cliff
2.1 Dealmaking biopharma verso il 2026
I report sulle M&A di fine 2025 indicano che il settore ha ripreso velocità:
- oltre 100 deal biopharma nel 2025, per un valore complessivo nell’ordine dei 130–140 miliardi di dollari;
- aspettative di attività elevata anche nel 2026, con space per sia bolt-on “string-of-pearls” sia qualche mega-deal;
- focus particolare su oncologia, neuroscienze e cardio-metabolico (obesità in primis).
I titoli dei giornali su JPM 2026 sono dominati dai nomi grossi (Merck su Revolution, Lilly e altri con deal da 10+ miliardi), ma la logica che spinge queste operazioni si riflette anche sul piano small-cap dove opera RNXT.
2.2 Il patent cliff che costringe le big pharma a comprare
Le analisi di JPM, banche e media mostrano lo stesso quadro di base:
- entro il 2030 oltre 150 miliardi di ricavi annui delle large-cap pharma/biotech sono attesi andare off-patent, spesso pari a ~30–35% del fatturato;
- allargando a marchi più piccoli, il totale a rischio entro il 2032 sale a **200–350 miliardi** a seconda delle stime;
- molti blockbuster oncologici (PD-1/PD-L1, TKIs) sono centrali in questo cliff, spingendo i big a cercare nuove asset oncologiche anni prima della scadenza.
Tradotto: le small-cap oncologiche tornano strutturalmente “in gioco”. Non significa che tutte verranno comprate, ma il “bid per l’innovazione” è tornato, e RNXT prova a raccontare la propria storia in questo contesto, fra JPM e ASCO GI.
3. Precision oncology e piattaforme interventional
3.1 Un mercato che raddoppia in silenzio
I report di mercato stimano il precision oncology market globale intorno ai 100–110 miliardi di dollari nel 2023–2024, con proiezioni verso 200–230 miliardi entro il 2032, a un CAGR di circa il 9–10%.
I driver principali:
- aumento di genomica, biomarcatori e companion diagnostics;
- più approvazioni di terapie mirate e tumor-agnostic;
- integrazione di AI e big data in diagnostica e terapia;
- maggiore uso di liquid biopsy e NGS in follow-up.
La maggior parte dell’attenzione è sull’aspetto molecolare (farmaci targettizzati, NGS, CDx). RNXT appartiene a un sottofilone diverso: precision oncology procedurale/interventional, dove il “targeting” avviene tramite la modalità di erogazione del farmaco, non tramite la molecola stessa.
3.2 Come si inserisce TAMP in questo quadro
La piattaforma TAMP di RenovoRx e il catetere RenovoCath cercano di rendere la chemio più “precisa”:
- concentrando il farmaco nella regione del tumore (segmento arterioso che lo irrora);
- riducendo l’esposizione sistemica e, potenzialmente, la tossicità sistemica;
- dando agli interventisti (IR/IO) un controllo molto localizzato sulla somministrazione.
In un mondo in cui la precision oncology è un tema forte per le M&A, RNXT è uno dei pochi micro-cap con una piattaforma interventional in Fase 3 nel pancreas, con device già approvato e un posizionamento chiaro in LAPC.
4. Sfondo regolatorio – accelerated approval, surrogati e OS
Negli ultimi mesi sono usciti diversi lavori sulle accelerated approval (AA) in oncologia:
- alcuni sottolineano che in una parte delle indicazioni i farmaci AA hanno portato benefici reali (PFS/OS) e anni di vita guadagnati grazie all’accesso anticipato;
- altri evidenziano come solo una frazione di questi farmaci dimostri poi un chiaro vantaggio di sopravvivenza entro 5 anni, portando la FDA a essere più severa (revoche, richieste di conferme più robuste).
Per RNXT, TIGeR-PaC non è un programma da AA classica: è uno studio di registrativa su OS con endpoint “duro”. Ma il contesto regolatorio conta lo stesso:
- i dati PK/PD di ASCO GI (esposizione sistemica, CA 19-9, ecc.) entrano nella narrativa su come valutare il rapporto rischio/beneficio di piattaforme di delivery nuove;
- se in LAPC la combinazione di dati meccanicistici + OS sarà convincente, TAMP potrà poi usare la stessa logica in altre indicazioni dove gli endpoint surrogati pesano di più.
In sintesi: i regolatori sono più selettivi sulle AA “deboli”, ma non sono chiusi all’innovazione – chiedono beneficio reale, e quando c’è, lo riconoscono.
5. Cosa implica tutto questo per RNXT dopo JPM
5.1 Tema giusto, rischi da micro-cap
Sovrapponendo i temi macro a RNXT:
- fit tematico: pancreas, precision/interventional, combo farmaco-dispositivo, Fase 3 – esattamente il tipo di asset che molti big dicono di voler valutare;
- valutazione: market cap nell’ordine di poche decine di milioni, microscopica rispetto al TAM ma con rischio elevato di volatilità e di funding;
- percorso dati: il vero “verdetto” è la readout OS 2027; ASCO GI 2026 e PanTheR sono tasselli intermedi che costruiscono credibilità.
La presentazione a JPM 2026 sostanzialmente mette RNXT sulla “mappa” dei player presenti a San Francisco: non come target di prima fila, ma come nome che, se TIGeR-PaC andrà bene, potrebbe rientrare nel radar M&A.
5.2 Possibili tipi di acquirenti
A livello concettuale, i potenziali interessati si dividono in tre famiglie:
- pharma oncologiche che vogliono rafforzarsi in pancreas e interventional oncology;
- medtech/interventional (cateteri, embolizzazione, IO devices) che vogliono aggiungere una piattaforma farmaco su una base di device esistente;
- ibridi (pharma con divisioni IO) che possono integrare sia la parte farmaco sia la parte device.
Nella pratica, un reale interesse strategico dipenderà quasi sicuramente da:
- dati OS finali di TIGeR-PaC e profilo di sicurezza;
- adozione reale di RenovoCath e andamento dei ricavi device;
- capacità di RNXT di mantenere la quotazione Nasdaq e limitare la diluizione.
5.3 Domande chiave da porsi ora
Dopo JPM, alcune domande diventano particolarmente interessanti:
- il management è realmente aperto a partnership/BD o punta a portare la storia avanti da solo?
- fino a dove arriva la cassa dopo ASCO GI e completamento randomizzazione TIGeR-PaC, e che tipo di finanziamento vediamo all’orizzonte?
- quanta della curiosità che si è vista attorno a RNXT a JPM si tradurrà in contatti concreti con strategici?
Non è una previsione di M&A, ma un cambio di contesto: rispetto a un paio d’anni fa, il vento macro è più favorevole per chi ha asset oncologici credibili. Il compito di RNXT resta lo stesso: consegnare dati e execution; se ci riuscirà, il mercato attorno sarà più ricettivo di quanto non fosse nel 2022–2023.
6. Disclaimer (IT)
Questo addendum ha finalità esclusivamente informative ed educative. Non costituisce consulenza finanziaria, raccomandazione personalizzata, invito al pubblico risparmio o suggerimento di acquisto/vendita di strumenti finanziari. Le informazioni derivano da documenti pubblici, comunicati societari e fonti di mercato ritenute affidabili al momento della redazione, ma possono cambiare nel tempo o contenere errori.
Chi legge deve sempre verificare i dati direttamente presso le fonti primarie (SEC, FDA, comunicati ufficiali, materiali di conferenza) e prendere decisioni in autonomia, eventualmente con il supporto di un consulente finanziario abilitato. Il trading su small-cap biotech e titoli catalyst-driven è altamente rischioso e può comportare la perdita totale del capitale.
Informazioni legali complete e privacy:
Disclaimer
·
Termini di Servizio, Privacy, Cookie Policy // Term of Service, Privacy, Cookie Policy
.
RNXT – ASCO GI 2026 PK/PD Addendum
Additional notes based on the January 8, 2026 RenovoRx press release ahead of the ASCO GI 2026 presentation.
ASCO GI 2026 PK/PD PRESS RELEASE – KEY TAKEAWAYS (JAN 8, 2026)
On January 8, 2026, RenovoRx released a new press release with additional detail on the TIGeR-PaC PK/PD sub-study that will be presented at ASCO GI 2026. The abstract, led by Dr. Paula Novelli (UPMC), is titled: “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial.”
Official PR: GlobeNewswire – January 8, 2026 .
Main new points from the PR:
- The analysis includes 16 patients across six TIGeR-PaC sites: 11 treated with TAMP + intra-arterial gemcitabine (IAG) and 5 treated with standard IV gemcitabine.
- TAMP + IAG produced reduced systemic gemcitabine levels and increased levels of the inactive metabolite compared with IV delivery.
- In the IAG group, investigators observed a direct correlation between higher inactive metabolite levels and reductions in CA 19-9, a biomarker commonly used to track chemotherapy response in pancreatic cancer.
- RenovoRx frames this as a drug-delivery strategy that could both increase local potency near the tumor and decrease chemotherapy side effects by limiting systemic exposure.
These data are mechanistic and come from a very small sample (16 patients total), but they strengthen the narrative that TAMP can meaningfully alter systemic exposure compared with IV gemcitabine. They do not replace or pre-empt the pivotal overall survival readout from TIGeR-PaC, which remains the binary value driver around 2027, but they add supportive “signal-building” evidence ahead of that moment.
Practically, the January 8 PR slightly upgrades the quality of the ASCO GI 2026 catalyst: investors can now expect concrete PK/PD numbers and CA 19-9 correlations, not just a generic “methodology” poster.
COMUNICATO ASCO GI 2026 PK/PD – PUNTI CHIAVE (8 GENNAIO 2026)
L’8 gennaio 2026 RenovoRx ha pubblicato un nuovo comunicato stampa con ulteriori dettagli sul sottostudio PK/PD di TIGeR-PaC che verrà presentato all’ASCO GI 2026. L’abstract, guidato dalla Dr.ssa Paula Novelli (UPMC), è intitolato: “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial.”
Comunicato originale: GlobeNewswire – 8 gennaio 2026 .
Punti nuovi principali dal PR:
- Analisi su 16 pazienti in sei centri TIGeR-PaC: 11 trattati con TAMP + gemcitabina intra-arteriosa (IAG) e 5 con gemcitabina EV standard.
- TAMP + IAG determina livelli sistemici di gemcitabina ridotti e livelli aumentati del metabolita inattivo rispetto alla somministrazione EV.
- Nel gruppo IAG è stata osservata una correlazione diretta tra aumento del metabolita inattivo e riduzione del CA 19-9, biomarcatore spesso usato per monitorare la risposta alla chemio nel pancreas.
- Il messaggio dell’azienda è che questo tipo di delivery può aumentare la potenza locale vicino al tumore e allo stesso tempo ridurre gli effetti collaterali grazie alla minore esposizione sistemica.
Si tratta di dati meccanicistici su un campione molto piccolo (16 pazienti totali), ma rafforzano la narrativa secondo cui TAMP modifica in modo significativo l’esposizione sistemica rispetto alla gemcitabina EV. Non sostituiscono e non anticipano la readout di sopravvivenza globale di TIGeR-PaC, che resta il vero evento binario atteso nel 2027, però aggiungono evidenza “di contesto” a favore della piattaforma.
In pratica, il comunicato dell’8 gennaio alza leggermente la qualità del catalyst ASCO GI 2026: conferma che ci si può aspettare numeri concreti di PK/PD e correlazioni con CA 19-9, non un semplice poster descrittivo della metodologia.
RenovoRx (RNXT) – TARGETED PANCREATIC CANCER & DRUG-DEVICE PLATFORM
Micro-cap (~37M $) clinical/commercial biotech developing a targeted drug-device platform (TAMP + RenovoCath) for solid tumors, with a pivotal Phase 3 trial in locally advanced pancreatic cancer (TIGeR-PaC) and a near-term catalyst at ASCO GI 2026. Pancreatic / LAPC Drug-Device Platform High Risk
Key numbers (checked)
Market cap (Jan 2026)≈37–38M $
Price (recent)≈1.0 $/share
52-week range0.70 – 1.69 $
Cash (Sep 30, 2025)10.0M $
Q3 2025 revenue≈0.27M $ (device sales)
Q3 2025 EPS-0.08 $
Shares outstanding36.65M (Nov 2025)
Platform & risk map
- RenovoCath, FDA-cleared dual-balloon catheter for targeted intra-arterial delivery.
- TAMP platform (Trans-Arterial Micro-Perfusion) to bathe tumors with high local drug concentrations while limiting systemic toxicity.
- RenovoGem (intra-arterial gemcitabine) in Phase 3 TIGeR-PaC for locally advanced pancreatic cancer (LAPC).
- ASCO GI 2026 PK/PD sub-study on January 9, 2026 – near-term mechanistic catalyst.
- PanTheR real-world registry for RenovoCath and growing device revenue base.
- Cash ~10M $, micro-cap size and Nasdaq bid-price notice imply dilution/listing risk.
Phase 3 LAPC
FDA-cleared device
Registry + commercial use
Financing risk
Binary 2027
2. QUICK DATA – COMPANY SNAPSHOT & STAGE
2.1 Basic identity
| Item | Data point |
|---|---|
| Company name | RenovoRx, Inc. |
| Ticker / Exchange | RNXT – Nasdaq Capital Market |
| Sector / Industry | Pharmaceuticals & Biotech / Biotechnology |
| Headquarters | Mountain View, California (USA) |
| Founded | 2009 |
| Employees | ≈10 |
| Market cap (early Jan 2026) | ≈37–38M $ |
| 52-week range | 0.70 – 1.69 $ |
| Website | renovorx.com |
2.2 Stage & platform
- Stage: clinical-stage with early commercial revenue.
- Lead asset: RenovoGem + RenovoCath in Phase 3 TIGeR-PaC for LAPC.
- Platform: TAMP (Trans-Arterial Micro-Perfusion) for local high-concentration delivery with reduced systemic exposure.
- Device: RenovoCath dual-balloon catheter – FDA-cleared for localized arterial occlusion and infusion.
- Other programs: PanTheR registry in solid tumors and potential TAMP indications beyond pancreas.
2.3 Cash & financial position (Q3 2025)
- Cash & equivalents (Sep 30, 2025): 10.0M $.
- Q3 2025 operating expenses: R&D ~1.7M $, SG&A ~1.7M $ (total ~3.4M $).
- Q3 2025 revenue: ~266k $ (RenovoCath), EPS -0.08 $.
- Management expects current cash to fund RenovoCath commercialization and completion of TIGeR-PaC enrollment in early 2026.
1. WHY RNXT IS ON THE “SMALL CAPS OF THE MOMENT” LIST
RenovoRx (RNXT) is an under-the-radar micro-cap that sits at the intersection of pancreatic cancer, targeted drug delivery, and drug-device combo – a profile that is rare among tiny biotech names.
The company is running a pivotal Phase 3 trial (TIGeR-PaC) in locally advanced pancreatic cancer (LAPC), using its TAMP platform and RenovoCath catheter to deliver gemcitabine intra-arterially (RenovoGem) and comparing it directly against standard IV gemcitabine + nab-paclitaxel. The trial has already passed two interim analyses with the DMC recommending it continue, and final data are guided for 2027.
The immediate reason RNXT deserves a place on a catalyst watchlist is the ASCO GI 2026 presentation on January 9, 2026, where investigators will present pharmacokinetic and pharmacodynamic data from a TIGeR-PaC sub-study comparing systemic drug levels after intra-arterial gemcitabine via RenovoCath vs standard IV therapy. It is not the final OS readout, but it is a rare, time-stamped catalyst on a name that many investors are not watching closely.
In short: RNXT is a high-risk, high-volatility micro-cap with a real Phase 3 in LAPC, an FDA-cleared device already generating initial revenues, and a near-term data presentation at a major GI oncology conference. If the PK/PD data strongly support TAMP’s safety and exposure profile, it can shift sentiment ahead of the final OS readout.
3. BUSINESS MODEL – DRUG-DEVICE PLATFORM IN ONCOLOGY
3.1 TAMP: Trans-Arterial Micro-Perfusion
TAMP is RenovoRx’s core therapy platform. The concept:
- Use RenovoCath to temporarily occlude a segment of an artery feeding the tumor.
- Infuse chemotherapy intra-arterially so that it permeates through the arterial wall into the tumor region.
- Aim for high local drug concentrations with reduced systemic exposure compared to IV dosing.
In LAPC, where systemic chemo is often poorly tolerated and only modestly effective, this formulation – hitting the tumor region while sparing the rest of the body – has clear intuitive appeal.
3.2 RenovoCath – the device backbone
RenovoCath is an FDA-cleared dual-balloon catheter used both:
- as the delivery backbone for RenovoGem in TIGeR-PaC, and
- as a stand-alone commercial product for interventional oncology / radiology teams in solid tumors.
First commercial purchase orders arrived in late 2024; 2025 updates describe repeat orders and expansion to additional high-volume centers, including NCI-designated cancer centers.
3.3 Business mix
- Short term: revenue is almost entirely from RenovoCath device sales.
- Medium term: TIGeR-PaC results will determine whether RenovoGem becomes a commercial drug-device combo.
- Long term: TAMP could be extended to other solid tumors if LAPC is successful.
4. PIPELINE – TIGeR-PaC, SUB-STUDIES & REGISTRY
4.1 TIGeR-PaC Phase 3 – LAPC backbone
**TIGeR-PaC** is a randomized Phase 3 trial in locally advanced, unresectable pancreatic cancer.
- Experimental arm: RenovoGem (gemcitabine IA via RenovoCath) + radiation.
- Control arm: standard IV gemcitabine + nab-paclitaxel + radiation.
Key design details:
- Planned enrollment: 114 patients (57 per arm).
- Primary endpoint: overall survival (OS).
- Final analysis at 86 deaths.
As of August 2025:
- Randomized patients: 95.
- Events: 61 deaths, triggering the second interim analysis.
- DMC recommendation: continue TIGeR-PaC as planned.
RenovoRx guides for enrollment completion in early 2026 and final OS data in 2027.
4.2 PK/PD sub-study – ASCO GI 2026 catalyst
The TIGeR-PaC PK/PD sub-study focuses on systemic exposure differences between intra-arterial and IV administration:
- Compares plasma gemcitabine levels after IA delivery via RenovoCath vs IV gemcitabine + nab-paclitaxel.
- Additional PK/PD data building on earlier analyses presented at ASCO GI 2023 and 2025.
- Abstract accepted at **ASCO GI 2026**; presentation on **January 9, 2026** in San Francisco.
A clear reduction in systemic exposure with TAMP, without compromising local effect, would support the idea that RenovoGem can offer better tolerability at a given efficacy level than standard IV regimens.
4.3 PanTheR registry – real-world RenovoCath
**PanTheR (NCT06805461)** is a multi-center post-marketing registry that tracks RenovoCath’s use in solid tumors.
- Collects long-term safety and outcome data from routine clinical practice.
- First patient treated at University of Vermont Cancer Center; additional centers like Baptist Health Miami Cancer Institute and UPMC have joined.
- Centers purchase RenovoCath directly for registry use – blending clinical and commercial activity.
5. DEVICE COMMERCIALIZATION – RENOVOCATH STAND-ALONE
RenovoCath’s commercial rollout is still early but provides a non-trivial difference vs pure pre-revenue peers:
- First purchase orders in late 2024; repeat orders and new centers in 2025.
- Q2/Q3 2025 show sequential growth in device revenues, albeit from a low base.
Success in TIGeR-PaC would likely create a step-change in adoption; even without it, the device has a path to moderate growth in the hands of interventional specialists.
6. FINANCIALS, CASH RUNWAY & DILUTION RISK
6.1 Cash & burn
- Cash & equivalents (Sep 30, 2025): 10.0M $.
- Quarterly operating expenses ~3.4M $ (R&D + SG&A).
- Revenue Q3 2025: ~266k $; EPS -0.08 $.
Management believes current cash will support operations through RenovoCath commercialization efforts and completion of TIGeR-PaC enrollment, but not necessarily through final data, submission and launch.
6.2 Listing & financing risk
- RNXT received a Nasdaq notice on December 31, 2025 for non-compliance with the $1.00 minimum bid requirement.
- The company has 180 days (until June 30, 2026) to regain compliance, with a potential additional 180-day extension.
- If the share price does not recover, a reverse split and/or further equity issuance may be needed.
For investors, this means **equity dilution and technical listing risk** are integral parts of the RNXT story.
7. STOCK PERFORMANCE, LIQUIDITY & VOLATILITY
- Share price (early Jan 2026): ~1.0 $.
- 52-week range: 0.70 – 1.69 $.
- Market cap: ~37–38M $.
- Average volume: ~300–350k shares/day.
- Short interest: low (~1–2% of float, 2–3 days to cover).
The micro-cap profile means that even modest newsflow (trial updates, registry, financings) can produce large percentage moves, in both directions.
8. ANALYST VIEW & EXPECTATIONS
Analyst coverage is thin but not zero:
- Aggregators show 3–4 analysts following RNXT, with overall bias in the **Buy/Strong Buy** area.
- Average 12-month price targets cluster between **5.5–7.7 $**, implying large upside from current levels – a reflection of binary risk rather than conservative modelling.
- EPS estimates remain negative over the forecast horizon.
In other words, the Street treats RNXT as a speculative Phase 3 story with significant upside if TIGeR-PaC succeeds and obvious downside if it doesn’t.
9. 2025–2027 TIMELINE – HOW THE STORY COULD UNFOLD
2025 – COMMERCIAL START & SECOND INTERIM
First RenovoCath commercial orders (late 2024) and repeat orders through 2025.
Launch of the PanTheR registry. In Q2 2025 the second pre-specified TIGeR-PaC interim analysis occurs at the 52nd death;
the DMC reviews the data and recommends continuing the trial.
EARLY 2026 – ENROLLMENT COMPLETION & ASCO GI
RenovoRx expects to complete randomization of the remaining TIGeR-PaC patients (from 95 to 114).
On January 9, 2026, ASCO GI hosts the PK/PD sub-study presentation, providing a high-profile look at TAMP’s
impact on systemic gemcitabine exposure.
2027 – FINAL TIGeR-PaC OS READOUT (ESTIMATE)
With 61 of 86 required events already observed by mid-2025 and ongoing follow-up, both company commentary and external
interviews point to **2027** as the realistic window for final OS data. That readout will determine whether RenovoGem/TAMP
becomes part of the standard of care in LAPC or remains an experimental approach.
10. CATALYST WINDOW (NEXT 12–24 MONTHS)
| Horizon | Catalyst | Comment |
|---|---|---|
| Very near term | ASCO GI 2026 PK/PD sub-study (Jan 9, 2026) | Data on systemic exposure with IA gemcitabine vs IV; may influence perception of TAMP’s risk/benefit profile. |
| Early/mid 2026 | TIGeR-PaC enrollment completion | Formal announcement of 114 randomized patients; operational de-risking. |
| 2026 | PanTheR registry updates | Number of centers and patients enrolled; early real-world safety and effectiveness signals. |
| 2026 | RenovoCath revenue trajectory | Sequential growth in device revenue and expanding footprint in high-volume IO/IR centers. |
| 2027 | Final TIGeR-PaC OS readout | Binary, high-impact event; determines the future of RenovoGem in LAPC. |
| Ongoing | Financing / Nasdaq compliance | Equity raises, potential reverse split, or strategic funding to extend runway. |
11. SENTIMENT (REDDIT / STOCKTWITS / X – NON-PROFESSIONAL)
RNXT is not a meme giant, but it has a small, vocal group of followers in the biotech corners of Reddit and Stocktwits:
- Bulls emphasize:
- Phase 3 status in LAPC rather than preclinical speculation;
- an FDA-cleared device already on the market;
- the ASCO GI 2026 catalyst as a potential “sleeper” event.
- Skeptics emphasize:
- tiny market cap and limited cash;
- history of small revenue misses and ongoing dilution risk;
- Nasdaq bid-price notice and reverse-split risk.
Overall sentiment is **swingy**: interest spikes around press releases and fades in quiet periods, with the low float amplifying price moves.
12. PEER GROUP & COMPETITIVE CONTEXT
RNXT’s position is unusual enough that it doesn’t slot neatly into classic peer buckets:
- Pancreatic cancer therapies: FOLFIRINOX, gemcitabine + nab-paclitaxel and experimental agents are competitors, but none employ the same IA catheter-based delivery.
- Drug-device interventional oncology: some analogues in chemoembolization or radioembolization, yet few with a Phase 3 LAPC trial based on a dual-balloon catheter.
- Targeted delivery platforms: conceptually similar to ADCs or nanoparticles, but TAMP is procedural rather than molecular.
This uniqueness can be an advantage (less crowding, clearer narrative) but also a risk (less validation from peers and benchmarks).
13. KEY QUESTIONS TO ASK ABOUT RNXT
- Will ASCO GI 2026 PK/PD data clearly demonstrate a systemic exposure advantage for TAMP vs IV chemotherapy?
- Can RenovoRx complete TIGeR-PaC enrollment and follow-up without funding or protocol issues?
- Will PanTheR real-world data be strong enough to support hospital and payer adoption of RenovoCath?
- How much dilution will be required between now and final data in 2027?
- Is the potential reward aligned with the investor’s tolerance for single-trial micro-cap risk?
14. SYNTHESIS – WHAT RNXT REALLY IS
Stripped of hype, RNXT is:
- a micro-cap clinical-stage company with a Phase 3 LAPC trial and an FDA-cleared device already in use;
- a bet on a catheter-based targeted delivery platform that will soon face a high-profile PK/PD test at ASCO GI;
- financially fragile, with limited cash and a likely need for further financing ahead of final OS data;
- ultimately binary around 2027, when TIGeR-PaC’s final OS results will either unlock value or force a reset.
This report is not a buy/sell recommendation, but a map of where RNXT stands going into ASCO GI 2026 and how the next 18–24 months could unfold.
15. INSIDER OWNERSHIP & CEO PROFILE
15.1 Insider ownership snapshot
- Insider ownership: **≈9–11%** of outstanding shares, according to Fintel, MarketBeat and WallStreetZen.
- Total insider shares: ~3.0M out of ~36.6M outstanding.
- Key individual insider: **Dr. Ramtin Agah**, founder, holds ≈1.7–1.8M shares (~4–5% of the company).
Overall, insider ownership is meaningful for a micro-cap: founders and executives have real skin in the game, though not to the point of tight control.
15.2 CEO – Shaun R. Bagai (curriculum)
Shaun R. Bagai has served as CEO and director of RenovoRx since **June 2014**.
- Over **15–20 years of medtech experience**, across clinical research, market development and commercial roles.
- Previously led **Global Market Development for HeartFlow**, managing its largest clinical trial and early international commercialization.
- Played a key role in building the **European renal denervation market** at Ardian, later acquired by Medtronic in 2011.
- Earlier experience at TransVascular and Medtronic in novel cardiovascular interventions.
Bagai’s profile is that of a seasoned **interventional medtech operator** rather than a classic small-biotech scientist: this fits RNXT’s positioning as a catheter-based oncology platform that requires buy-in from interventionalists and hospitals.
16. INSTITUTIONAL OWNERSHIP & HOLDER LANDSCAPE
16.1 Institutional stake – who owns RNXT?
- Institutional ownership: **≈19–22%** of shares outstanding.
- Retail/free float: roughly **65–70%** of shares.
For a 37M $ micro-cap, this is a fairly solid institutional base: not dominated by one fund, but with multiple specialist investors involved.
16.2 Major institutional holders (indicative)
- AIGH Capital Management – largest holder, with ≈3.4M shares (≈9–10% stake as of mid-2025).
- Vanguard Group – ~1.4–1.5M shares (≈3.8–4.0%).
- Additional holders include Corsair Capital, Stonepine Capital, Renaissance Technologies, Citadel Advisors and smaller funds.
This mix means that RNXT is not purely a retail sandbox: **specialist hedge funds and quant funds** are watching the story, which can amplify both buying and selling when data or financing news hit the tape.
17. Biotech Catalyst Calendar
To keep RNXT’s ASCO GI 2026 presentation and the later TIGeR-PaC milestones in context with the rest of the biotech space, you can refer to the Merlintrader Biotech Catalyst Calendar, updated with key PDUFA dates, readouts and high-impact events.
Open the Biotech Catalyst Calendar2. DATI RAPIDI – SNAPSHOT AZIENDALE
2.1 Identità
| Voce | Dato |
|---|---|
| Nome società | RenovoRx, Inc. |
| Ticker / Borsa | RNXT – Nasdaq Capital Market |
| Settore / Industria | Farmaceutici & Biotech / Biotecnologie |
| Sede | Mountain View, California (USA) |
| Fondata | 2009 |
| Dipendenti | ≈10 |
| Market cap (inizio gen 2026) | ≈37–38M $ |
| Range 52 settimane | 0,70 – 1,69 $ |
| Sito web | renovorx.com |
2.2 Stadio & piattaforma
- Stadio: biotech clinica con primi ricavi commerciali.
- Asset principale: RenovoGem + RenovoCath in Fase 3 TIGeR-PaC su LAPC.
- Piattaforma: TAMP (Trans-Arterial Micro-Perfusion) per delivery mirato e riduzione dell’esposizione sistemica.
- Dispositivo: RenovoCath – catetere dual-balloon approvato FDA per occlusione/infusione arteriosa locale.
- Altri programmi: registro PanTheR e possibili estensioni TAMP ad altri tumori solidi.
2.3 Cassa & posizione finanziaria (Q3 2025)
- Cassa (30/09/2025): 10,0M $.
- Spese operative Q3 2025 ~3,4M $ (R&D + SG&A).
- Ricavi Q3 2025: ~266k $ da RenovoCath; EPS -0,08 $.
- La cassa è stimata sufficiente per completare la commercializzazione iniziale del device e l’arruolamento di TIGeR-PaC.
1. PERCHÉ RNXT È NELLA LISTA “SMALL CAPS DEL MOMENTO”
RenovoRx (RNXT) è una micro-cap relativamente ignorata che si colloca in un punto insolito: cancro del pancreas, drug delivery mirato e combo dispositivo + farmaco.
L’azienda sta conducendo un trial pivotale di Fase 3 (TIGeR-PaC) nel pancreas localmente avanzato (LAPC), usando la piattaforma TAMP e il catetere RenovoCath per somministrare gemcitabina in modo intra-arterioso (RenovoGem) e confrontandola con lo standard IV gemcitabina + nab-paclitaxel. Il trial ha superato due analisi ad interim con raccomandazione del DMC a proseguire e i dati finali di OS sono stimati per il 2027.
Il motivo immediato per cui RNXT merita un posto nella watchlist è la **presentazione all’ASCO GI 2026 il 9 gennaio 2026**, dove verranno mostrati dati PK/PD da un sottostudio di TIGeR-PaC che confronta i livelli sistemici di gemcitabina dopo infusione intra-arteriosa via RenovoCath rispetto alla chemio IV standard.
In sintesi: RNXT è una **micro-cap ad alto rischio** con un trial di Fase 3 reale in LAPC, un dispositivo approvato FDA che inizia a generare ricavi, e un catalyst ravvicinato all’ASCO GI 2026. Se il profilo PK/PD confermerà un vantaggio in termini di esposizione sistemica, il titolo può beneficiare di un rerating ben prima della readout finale.
3. MODELLO DI BUSINESS – PIATTAFORMA DRUG-DEVICE
3.1 TAMP – Trans-Arterial Micro-Perfusion
TAMP è il cuore tecnologico di RenovoRx:
- RenovoCath isola tramite due palloncini un tratto di arteria che irrora il tumore;
- la chemio viene infusa in modo intra-arterioso, diffondendosi attraverso la parete verso il tessuto tumorale;
- l’obiettivo è alte concentrazioni locali con esposizione sistemica più bassa rispetto all’IV.
3.2 RenovoCath
RenovoCath è un catetere dual-balloon **già approvato FDA**. Serve:
- come backbone per RenovoGem in TIGeR-PaC;
- come dispositivo stand-alone venduto a centri IO/IR per tumori solidi, anche tramite il registro PanTheR.
3.3 Mix di business
- oggi: ricavi quasi esclusivamente da RenovoCath;
- domani: se TIGeR-PaC è positivo, RenovoGem può diventare prodotto combinato ad alto valore;
- nel lungo: TAMP potrebbe estendersi oltre il pancreas.
4. PIPELINE – TIGeR-PaC, SOTTOSTUDI E REGISTRO
4.1 TIGeR-PaC Fase 3 – LAPC
TIGeR-PaC è un trial randomizzato di Fase 3 in **pancreas localmente avanzato non resecabile**.
- Braccio sperimentale: RenovoGem + TAMP via RenovoCath + radioterapia;
- Braccio controllo: gemcitabina + nab-paclitaxel IV + radioterapia.
- arruolamento target: 114 pazienti (57 per braccio);
- endpoint primario: OS;
- analisi finale a 86 decessi.
Ad agosto 2025: 95 pazienti randomizzati, 61 decessi, seconda interim analisi superata con raccomandazione DMC a proseguire.
La società guida per completare l’arruolamento all’inizio del 2026 e per i dati finali nel 2027.
4.2 Sottostudio PK/PD – catalyst ASCO GI 2026
Il sottostudio PK/PD di TIGeR-PaC confronta l’esposizione sistemica di gemcitabina:
- IA via RenovoCath (TAMP) vs IV gemcitabina + nab-paclitaxel.
- Dati PK/PD aggiuntivi rispetto alle analisi presentate ad ASCO GI 2023 e 2025.
- Presentazione all’ASCO GI 2026 il 9 gennaio 2026 a San Francisco.
4.3 Registro PanTheR
**PanTheR (NCT06805461)** è un registro osservazionale multi-centro sull’uso reale di RenovoCath nei tumori solidi.
- il primo paziente è stato trattato all’University of Vermont Cancer Center;
- altri centri (Baptist Health Miami, UPMC, ecc.) si sono aggiunti nel corso del 2025;
- i centri acquistano RenovoCath per utilizzarlo nel registro (quindi dati + ricavi).
5. COMMERCIALIZZAZIONE DEL DISPOSITIVO
La vendita di RenovoCath è ancora agli inizi, ma crea una base diversa rispetto alle biotech zero-ricavi:
- ordini iniziali a fine 2024 e riordini nel 2025;
- ricavi in crescita sequenziale nel 2025, anche se ancora su numeri ridotti.
6. FINANZA, RUNWAY E DILUIZIONE
6.1 Cassa e burn
- cassa 10M $ al 30/09/2025;
- spese operative ~3,4M $ a trimestre;
- ricavi Q3 2025 ~266k $, EPS -0,08 $.
6.2 Rischio listing/finanziamenti
- notifica Nasdaq per prezzo sotto 1 $ (dicembre 2025), con deadline iniziale giugno 2026;
- probabile bisogno di nuovo capitale (equity o deal strategici) prima del 2027.
7. COMPORTAMENTO DEL TITOLO
- prezzo ~1 $; range 52 settimane 0,70–1,69 $; market cap ~37–38M $.
- volume medio ~300–350k azioni/giorno; short interest basso (~1–2% del float).
Micro-cap tipica: bassa liquidità relativa, movimenti violenti su news e su eventuali operazioni di funding.
8. STIME ANALISTI
- copertura ridotta (3–4 analisti) con bias medio fra Hold e Buy/Strong Buy;
- target price medi in area 5,5–7,7 $, che riflettono alta optionalità più che prudenza;
- EPS attesi negativi per tutto l’orizzonte pre-readout.
9. TIMELINE 2025–2027
2025 – AVVIO COMMERCIALE E SECONDA INTERIM
Prime vendite RenovoCath, lancio del registro PanTheR, seconda interim di TIGeR-PaC con DMC che raccomanda di proseguire.
INIZIO 2026 – COMPLETAMENTO ARRUOLAMENTO & ASCO GI
Completamento arruolamento TIGeR-PaC; il 9 gennaio 2026 i dati PK/PD al congresso ASCO GI diventano catalyst chiave.
2027 – READOUT FINALE OS
Con 61 eventi già maturati e target 86 per la finale, 2027 è la finestra più plausibile per la readout di OS.
È il vero “verdetto” sulla strategia TAMP in LAPC.
10. FINESTRA CATALYST
| Orizzonte | Catalyst | Nota |
|---|---|---|
| Gennaio 2026 | ASCO GI 2026 – sottostudio PK/PD | Dati su esposizione sistemica IA vs IV; catalizzatore di sentiment sul rischio/tossicità. |
| 2026 | Completamento arruolamento TIGeR-PaC | Deriska la parte operativa. |
| 2026 | Aggiornamenti PanTheR | Centri/pazienti, first look real-world. |
| 2026 | Trend ricavi device | Crescita sequenziale RenovoCath. |
| 2027 | Readout finale OS TIGeR-PaC | Evento binario di massima importanza. |
| Continuo | Finanziamenti / compliance Nasdaq | Nuove emissioni o mosse tecniche sul listino. |
11. SENTIMENT (REDDIT / STOCKTWITS / X)
Il titolo non è mainstream, ma circola nelle community biotech:
- i bullish parlano di Fase 3 “vera”, device già approvato e catalyst ASCO GI;
- gli scettici guardano a cassa, diluizione e rischio delisting.
12. PEER GROUP E CONCORRENZA
RNXT non ha un peer diretto perfetto:
- competizione terapia pancreas: regimi sistemici e studi concorrenti;
- spazio interventional oncology: altre soluzioni loco-regionali ma con meccaniche diverse;
- piattaforme di delivery: simile per logica a ADC/nano, ma qui la soluzione è procedurale via catetere.
13. DOMANDE CHIAVE
- ASCO GI 2026 mostrerà un vantaggio PK/PD convincente?
- L’azienda arriverà alla readout finale senza problemi di cassa o protocollo?
- PanTheR e la vendita device convinceranno centri e payer a lungo termine?
- La diluizione necessaria fino al 2027 sarà accettabile per gli attuali azionisti?
14. SINTESI FINALE
RNXT è:
- una micro-cap clinica con Fase 3 in LAPC + device approvato;
- una scommessa su una piattaforma di delivery IA in un’area ad alto unmet need;
- finanziariamente fragile, con rischio strutturale di diluizione/listing;
- una storia destinata a essere **binaria nel 2027** con la readout TIGeR-PaC.
15. INSIDER & CEO
15.1 Insider ownership
- insider ownership complessiva ~9–11% del capitale (≈3M azioni su 36,6M).
- l’insider individuale principale è Ramtin Agah, fondatore, con ~1,7–1,8M azioni (~4–5%).
15.2 CEO Shaun R. Bagai – curriculum
- CEO e direttore di RenovoRx dal 2014;
- oltre 15 anni di esperienza in medtech (TransVascular, Medtronic, Ardian, HeartFlow);
- ha guidato Global Market Development per HeartFlow, gestendo il trial clinico principale e l’espansione internazionale;
- ha contribuito allo sviluppo del mercato europeo della renal denervation per Ardian (acquisita da Medtronic nel 2011).
16. ISTITUZIONALI & AZIONARIATO
16.1 Breakdown
- istituzionali: circa 19–22% delle azioni;
- insider: ~9–11%; retail: ~67–70% del capitale.
16.2 Principali istituzionali
- AIGH Capital Management: primo azionista istituzionale, con ~3,4M azioni (≈9–10%);
- Vanguard Group: ~1,4–1,5M azioni (~3,8–4%);
- altri: Corsair Capital, Stonepine, Renaissance Technologies, Citadel, ecc.
Per una micro-cap, è un azionariato abbastanza serio: non dominato da un singolo fondo, ma nemmeno solo retail.
17. Biotech Catalyst Calendar
Per seguire RNXT (ASCO GI 2026 e, più avanti, la readout TIGeR-PaC) nel contesto degli altri catalyst biotech, puoi usare il Biotech Catalyst Calendar aggiornato su Merlintrader.
Vai al Biotech Catalyst CalendarScanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
